Effect of Enteral Bovine Lactoferrin in Preterm Infants
to Evaluate the Effect of Oral Administration of Bovine Lactoferrin on the Neurobehavioral Performance of Preterm Neonates

About this trial
This is an interventional supportive care trial for to Evaluate the Effect of Oral Administration of Bovine Lactoferrin on the Neurobehavioral Performance of Preterm Neonates
Eligibility Criteria
Inclusion Criteria: Stable preterm neonates gestational age less than 35 weeks younger than 72 hours at randomization have initiated enteral feds. Exclusion Criteria: 1. Neonates with underlying gastrointestinal problems that prevent oral intake. 2. Neonates with predisposing conditions that profoundly affect growth and development (chromosomal abnormalities, structural brain anomalies, severe congenital abnormalities). 3. Neonates with a history of perinatal hypoxia. 4. Neonates with a family background of cow milk allergy. 5. Evidence of feeding difficulties or formula intolerance, such as vomiting or poor intake.
Sites / Locations
- Ain Shams University Hospitals
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
lactoferrin group
control group
Neonates will receive a daily dose of 150 mg/kg body weight per day (up to a maximum of 300 mg/day) of bovine lactoferrin and will be prepared for administration by addition by syringe of sterile water (4 mL) orally or through gavage feeding, once the infant's enteral feed volume is more than 12 mL/kg per day until 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer. (Asztalos.,et al 2020)
Neonates will receive their routine feds and will not receive lactoferrin.